# Seaport Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seaport-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.seaporttx.com
- Total disclosed funding: $326M
- Latest round: Series B (Oct 18, 2024)
- Investors on record: 10

## About

Based in Massachusetts, US, and founded in 2024 by co-founders Steven Paul and Daphne Zohar, Seaport Therapeutics, Inc. operates as a healthtech-based company providing biotherapeutics clinical-stage to develop neuropsychiatric medicines. In May 2026, General Atlantic, L.P. raised an 11.5% stake in Seaport Therapeutics, Inc. common stock. The firm trades on the Nasdaq Global Select Market under the ticker symbol "SPTX" Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. developed a Glyph technology platform, which is designed to enable oral bioavailability, bypass first-pass metabolism, and mitigate hepatotoxicity and other adverse effects associated with traditional medications in this space. The company offers expertise with solutions to patients living with conditions such as major depression with anxiety, generalized anxiety disorder, and other mood and neuropsychiatric disorders. In addition, the firm offers various programs such as SPT-300 (Glyph Allopregnanolone), SPT-320 (Glyph Agomelatine), and SPT-348 (non-hallucinogenic neuroplastogen).

## Funding rounds

- Series B, Oct 18, 2024, $226M — ARCH Venture Partners, Sofinnova Investments, T Rowe Price, General Atlantic, CPP Investment Board, Invus [DUP], Third Rock Ventures, Goldman Sachs Asset Management, Foresite Capital, PureTech Health plc
- Series A, Apr 7, 2024, $100M — ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health plc

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- PureTech Health plc — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series B
- CPP Investment Board — Series B
- Invus [DUP] — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B